$HIMS

FTC Continues Investigation into Hims & Hers Health, Inc. as Lowey Dannenberg Files Class Action Complaint on Behalf of Consumers

Lowey Dannenberg filed a consumer class action against Hims & Hers Health, alleging the company misrepresented telehealth privacy and shared sensitive health data with third-party advertisers without consent, and allegedly used “free consultation” ads while charging recurring prescription subscriptions and making cancellation difficult. The FTC, with California and Utah regulators, filed a civil enforcement complaint on July 29, 2026.

Original reporting
Published Aug 11, 2026, 7:30 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 11, 2026, 8:01 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefRegulation
Primary signal
$HIMS
Bearish
medium confidence
Mentioned
$HIMS
Relevance
7/10
alphai data visualization · based on globenewswire.com
Decision brief

The 30-second read

$HIMSBearishMed
01

Why it matters

The new class action alleges privacy misrepresentation and unauthorized sharing of sensitive health information with third-party advertisers, adding litigation exposure on top of the FTC case.

02

Market read

Traders may reassess legal and compliance risk for Hims & Hers following the FTC enforcement filing and the parallel consumer class action alleging ad-tech sharing of health data.

03

What to watch

The article is law-firm promotional copy and does not include court rulings, penalties, or quantified damages; actual financial impact may be delayed until discovery, motions, or settlement.

Relevance 7/10Novelty 6/10Timing: today, after-hours legal/regulatory headline risk

Background

The FTC issued a Civil Investigative Demand in 2023 and later filed a civil enforcement complaint on July 29, 2026, joined by California and Utah consumer protection authorities.

Company-level read

Ticker impact

$HIMSBearishMedium confidence
Context

FTC civil enforcement action and a new consumer class action allege Hims & Hers misrepresented privacy and shared sensitive health data with advertisers.

Expected impact

Near-term downside bias on risk headlines; follow-through depends on settlement scope and any mandated data-sharing changes.

Evidence & confidence

The article discloses a fresh FTC enforcement filing date and a newly filed class action tied to alleged privacy misrepresentations and ad-tech data sharing, which typically increases legal and compliance uncertainty.

Market effects

Raises scrutiny for telehealth and direct-to-consumer health platforms using ad pixels and SDKs, potentially pressuring peers’ privacy/compliance spend.

US-focused consumer protection and privacy enforcement could spill into other state AG actions and class-action filings.

US privacy enforcement may reinforce broader global data-protection expectations for health data processing and ad-tech tracking.

Counterpoint

If Hims & Hers can demonstrate adequate disclosures or quickly implement compliance changes, the market may price the risk as manageable rather than existential.

Key entities

  • Hims & Hers Health, Inc.

    Telehealth platform at the center of FTC enforcement and a newly filed consumer class action over alleged privacy and billing practices.

  • Federal Trade Commission (FTC)

    Filed a civil enforcement complaint alleging violations of the FTC Act and ROSCA, among other claims.

  • Lowey Dannenberg, P.C.

    Filed the first consumer class action complaint and is seeking damages, restitution, and injunctive relief.

  • Meta Platforms, Inc.

    Named as an advertising platform allegedly receiving sensitive health data via pixels/SDKs.

  • Snap Inc.

    Named as an advertising platform allegedly receiving sensitive health data via pixels/SDKs.

Related articles

$HIMSMed

Hims & Hers stock trims losses following quarterly results

Hims & Hers Health (HIMS) shares fell about 3% before narrowing losses after its Q2 results. The company reported a per-share loss of $0.37 versus a $0.17 profit a year earlier, with gross margin at 64% from 76%. Results included an $81 million one-time cost tied to Eucalyptus acquisition, restructuring, and FTC-related legal reserves. The stock is down over 4% YTD.

$HIMSMedAI 8/10

Hims & Hers Q2 revenue beat offset by wider-than-expected loss

Hims & Hers Health reported Q2 revenue of $753.2 million, up 38% year over year and above analysts’ ~$699 million estimate. The company posted a wider-than-expected loss of $0.37 per share, citing restructuring charges tied to its branded GLP-1 shift. Subscribers rose 19% to nearly 2.9 million. It raised FY2026 revenue guidance to $3.1-$3.3 billion.

$HIMSMedAI 8/10

HIMS Q2 Deep Dive: AI Strategy and International Expansion Shape Telehealth Outlook

Hims & Hers Health (HIMS) reported Q2 CY2026 revenue of $753.2 million, up 38.2% year over year, and said next-quarter revenue guidance is $890 million at the midpoint. Non-GAAP loss was $0.09 per share. Management attributed results to AI-led engagement, specialty expansion, and the June Eucalyptus acquisition, while citing higher operating expenses and litigation costs.

$INTCMed

Stocks making the biggest moves premarket: Riot Platforms, Hims & Hers Health, Intel & more

Premarket movers included Intel, Hims & Hers Health, Riot Platforms, Plug Power, First Solar, Cardinal Health, and On Holding. Intel fell after upsizing a common stock offering to $20B. Hims & Hers shares dropped after trimming full-year EBITDA guidance and reporting a Q2 net loss. Riot rose on Q2 revenue above estimates. First Solar got a Baird upgrade with a $318 target. Cardinal Health edged up on EPS beat but revenue miss. On Holding fell after mixed results and lower revenue guidance.